MBA Pharmaceuticals Private Limited

MBA Pharmaceuticals Private Limited is a privately held pharmaceutical company established on February 26, 2014, in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U51397DL2014PTC265441. Its authorized and paid-up capital stands at ₹2 million each. The registered office is located at 4931, Plot No. 68, Second Floor, South Ansari Road, Daryaganj, New Delhi, Delhi, 110002.

MBA Pharmaceuticals specializes in the wholesale and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company exports to over 40 countries, primarily in the European Union, Middle East and North Africa (MENA), South Asian Association for Regional Cooperation (SAARC), Southeast Asia, African Gulf Cooperation Council (GCC), and Commonwealth of Independent States (CIS) regions.

As of the latest available data, the company has a modest annual turnover, with an employee count ranging from 11 to 50. The directors of MBA Pharmaceuticals are Jitender Kumar and Girish Kalra, both appointed on February 26, 2014.

MBA Pharmaceuticals operates manufacturing facilities compliant with international standards, including Good Manufacturing Practice (GMP) and ISO 9001:2015 certifications. These facilities are equipped to produce a range of pharmaceutical products, ensuring quality and safety in line with global requirements.

The leadership team of MBA Pharmaceuticals comprises:

• Jitender Kumar: Director since February 26, 2014.

• Girish Kalra: Director since February 26, 2014.

MBA Pharmaceuticals has established a presence in several regulated markets, including the European Union (EU), Middle East and North Africa (MENA) region, and South Asian Association for Regional Cooperation (SAARC) countries. The company exports a diverse portfolio of products, including oncology, hepatitis-C, nephrology, HIV, vaccines, rheumatic, branded and generic medicines, and COVID-19 products.

MBA Pharmaceuticals has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to international standards, such as Good Distribution Practice (GDP) and ISO 9001:2015 certifications, facilitates its entry into these markets.

MBA Pharmaceuticals demonstrates a diversified geographic strategy by exporting to over 40 countries across various regions, including the EU, MENA, SAARC, Southeast Asia, African GCC, and CIS countries. This broad market presence mitigates concentration risk and positions the company as a competitive player in the global pharmaceutical export sector.

Specific details regarding MBA Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company holds ISO 9001:2015 certification, indicating a commitment to quality management systems.

MBA Pharmaceuticals' manufacturing facilities are certified with Good Manufacturing Practice (GMP) and ISO 9001:2015, ensuring compliance with international quality standards. However, specific certifications such as WHO prequalification and EU GMP certificates are not publicly disclosed.

MBA Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, ensuring compliance with Indian regulatory standards. The company also possesses the necessary export No Objection Certificates (NOCs) for international trade.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to MBA Pharmaceuticals. The company's adherence to international standards, including ISO 9001:2015 and GMP certifications, reflects its commitment to regulatory compliance.

MBA Pharmaceuticals operates in a competitive landscape with numerous pharmaceutical exporters from India. While specific market share data is not publicly available, the company's diverse product portfolio and international certifications position it as a competitive entity in the global pharmaceutical export market.

MBA Pharmaceuticals' key differentiators include its compliance with international standards such as GDP and ISO 9001:2015, a diverse product portfolio encompassing oncology, hepatitis-C, nephrology, HIV, vaccines, rheumatic, branded and generic medicines, and COVID-19 products, and its export to over 40 countries across various regions.

MBA Pharmaceuticals focuses on the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's adherence to international standards and diverse product portfolio indicate a strategic direction aimed at expanding its global presence and competitiveness in the pharmaceutical export sector.

MBA Pharmaceuticals demonstrates a commitment to quality and regulatory compliance through its ISO 9001:2015 and GMP certifications. The company's export volume and consistency are evidenced by its presence in over 40 countries, including the EU, MENA, SAARC, Southeast Asia, African GCC, and CIS regions.

Importers should verify the following certifications when considering MBA Pharmaceuticals as a supplier:

• ISO 9001:2015: Confirms the company's adherence to quality management systems.

• Good Manufacturing Practice (GMP): Ensures compliance with international manufacturing standards.

• Good Distribution Practice (GDP): Verifies the company's compliance with distribution standards.

These certifications can typically be verified through the company's official website or by contacting the company directly.

When conducting due diligence on MBA Pharmaceuticals, consider the following steps:

• Verify Certifications: Confirm ISO 9001:2015, GMP, and GDP certifications.

• Assess Financial Health: Review the company's financial statements for profitability and growth trends.

• Evaluate Regulatory Compliance: Ensure adherence to CDSCO and state drug controller regulations.

• Review Export Documentation: Check for necessary export No Objection Certificates (NOCs).

• Inspect Product Portfolio: Assess the diversity and quality of the product range.

Red flags to watch for include expired certifications, inconsistent financial records, and lack of regulatory approvals. Recommended pre-order checks involve verifying the authenticity of certifications and assessing the company's reputation in the market.